Maximus (NYSE:MMS) Stock Rating Upgraded by StockNews.com

Maximus (NYSE:MMS) was upgraded by equities researchers at StockNews.com from a “hold” rating to a “buy” rating in a report issued on Thursday.

Separately, Raymond James upgraded shares of Maximus from a “market perform” rating to an “outperform” rating and set a $90.00 target price on the stock in a research note on Thursday, January 2nd.

Maximus Price Performance

Maximus stock opened at $69.86 on Thursday. The firm has a market capitalization of $3.99 billion, a P/E ratio of 13.97 and a beta of 0.72. Maximus has a one year low of $68.30 and a one year high of $93.97. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.49 and a quick ratio of 1.49. The business has a fifty day moving average price of $74.73 and a 200-day moving average price of $83.38.

Maximus (NYSE:MMS) last issued its earnings results on Thursday, February 6th. The health services provider reported $1.61 EPS for the quarter, topping the consensus estimate of $1.39 by $0.22. Maximus had a return on equity of 20.95% and a net margin of 5.78%. As a group, equities research analysts forecast that Maximus will post 5.95 EPS for the current year.

Insider Buying and Selling at Maximus

In related news, Director Raymond B. Ruddy purchased 3,490 shares of the business’s stock in a transaction on Thursday, December 12th. The stock was acquired at an average price of $71.46 per share, with a total value of $249,395.40. Following the purchase, the director now directly owns 112,520 shares in the company, valued at approximately $8,040,679.20. This represents a 3.20 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. Also, insider Michelle F. Link sold 2,208 shares of the firm’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $73.83, for a total transaction of $163,016.64. Following the sale, the insider now owns 6,567 shares in the company, valued at approximately $484,841.61. This trade represents a 25.16 % decrease in their position. The disclosure for this sale can be found here. Insiders have acquired a total of 7,063 shares of company stock valued at $502,017 in the last 90 days. Corporate insiders own 1.60% of the company’s stock.

Hedge Funds Weigh In On Maximus

A number of hedge funds and other institutional investors have recently modified their holdings of the company. V Square Quantitative Management LLC bought a new stake in Maximus in the 3rd quarter worth approximately $25,000. UMB Bank n.a. raised its stake in shares of Maximus by 79.8% during the fourth quarter. UMB Bank n.a. now owns 356 shares of the health services provider’s stock worth $27,000 after acquiring an additional 158 shares in the last quarter. Eastern Bank bought a new stake in shares of Maximus in the 4th quarter worth approximately $29,000. R Squared Ltd purchased a new stake in shares of Maximus in the 4th quarter valued at $54,000. Finally, IFP Advisors Inc boosted its stake in shares of Maximus by 62.4% in the 4th quarter. IFP Advisors Inc now owns 786 shares of the health services provider’s stock valued at $59,000 after purchasing an additional 302 shares in the last quarter. 97.21% of the stock is currently owned by hedge funds and other institutional investors.

Maximus Company Profile

Maximus, Inc operates as a provider of government services in the United States and internationally. It operates through three segments: U.S. Federal Services, U.S. Services, and Outside the U.S. The U.S. Services segment offers program eligibility support and enrollment; centralized multilingual customer contact centers, multichannel, and digital self-service options for enrollment; application assistance and independent health plan choice counseling; beneficiary outreach, education, eligibility, enrollment, and redeterminations; and person-centered independent disability, long-term sick, and other health assessments.